The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Japan

Trends Update — Shifting IP Constituencies: Perkin Elmer and Mylan in India, Branded Generics Everywhere and China’s R&D Budget all Point to Change

world_map_2002In our continuing Trends in 2009 series on shifting IP constituencies, we’ve been following increasing innovative activity in the developing world, and innovator pharma’s increasing moves towards generics and biosimilars.  This week saw updates on both fronts:

Bookmark and Share

Angiotech Expands and Reworks Baxter COSEAL Deal (for real)

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) reworked its COSEAL deal with Baxter International Inc.  For a $25 million one-time payment, Baxter will pick up the rights to COSEAL in Japan, completing a worldwide package, and will add additional fields of use for COSEAL, as well as rights to COSEAL derivatives. Baxter will owe no further royalty or milestone obligations to Angiotech.

Market reaction has been positive, with the stock up 18% so far today.

Bookmark and Share

Follow

Get every new post delivered to your Inbox.

Join 130 other followers